Colin Freund takes new CEO job at Modra Pharma; Compass recruits Pfizer, Biogen vets to C-suite
→ Amsterdam-based Modra Pharmaceuticals has tapped a permanent CEO to guide its pipeline of oral chemotherapies as it wraps up a Phase Ib/IIa study for the lead program — a tablet formulation of docetaxel. Colin Freund comes with fresh CEO experience at Que Oncology as well as a previous stints at Trangene and GPC Biotech. Eric van der Putten, the Aglaia Biomedical Ventures partner who was filling the role ad interim, will recede to a board director role. Meanwhile Edwin De Wit has also joined the company as head of oncology development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.